

Mai-Yee Luk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8334520/publications.pdf>

Version: 2024-02-01

15
papers

237
citations

1163117

8
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

331
citing authors

#	ARTICLE	IF	CITATIONS
1	An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma. <i>Cancers</i> , 2022, 14, 1923.	3.7	1
2	Incidence and Demographics of Nasopharyngeal Carcinoma in Cheung Chau Island of Hong Kong—A Distinct Geographical Area With Minimal Residential Mobility and Restricted Public Healthcare Referral Network. <i>Cancer Control</i> , 2021, 28, 107327482110471.	1.8	2
3	The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 626145.	2.8	9
4	Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies. <i>Oral Oncology</i> , 2021, 114, 105158.	1.5	7
5	Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6046-6046.	1.6	0
6	Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant. <i>Hepatology</i> , 2021, 74, 2580-2594.	7.3	43
7	Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 1148.	2.9	5
8	Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1417.	2.8	11
9	Phase II study of consolidative intensity-modulated radiation therapy following first-line palliative systemic chemotherapy for de novo previously untreated metastatic (M1) nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6524-6524.	1.6	2
10	Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. <i>British Journal of Cancer</i> , 2019, 121, 690-698.	6.4	19
11	Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. <i>Surgical Oncology</i> , 2019, 28, 228-235.	1.6	23
12	The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. <i>International Journal of Cancer</i> , 2019, 144, 1713-1722.	5.1	82
13	Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 40-54.	7.7	24
14	Prognostic role of pretreatment plasma EBV DNA on stage III nasopharyngeal carcinoma staged by AJCC/UICC 8 th edition TNM staging classification.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6055-6055.	1.6	0
15	Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 3457.	2.0	9